TOSHIBA-MATERIALS
20.7.2022 06:07:10 CEST | Business Wire | Press release
Toshiba Materials Co., Ltd. (President: Katsuaki Aoki) today announced a major investment in a new manufacturing facility for silicon nitride balls on the same site as its headquarters in Yokohama, Japan. The project has a budget of over 5-billion yen (approx. US$38 million) and is expected to see production start in November 2023. It will increase capacity by 50% against fiscal year 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220719006169/en/
Continued advances in automobile electrification requires solutions that go beyond higher voltage batteries and shorter charging times. One measure to reduce costs and improve performance is the integration of motors and inverters. Although this increases risk of electrolytic corrosion[1] in motor bearings[2] , the problem can be overcome with hybrid bearings, which replace standard steel balls with ceramic balls with steel inner and outer races. Advantages of high reliability, excellent strength and superior wear resistance are increasingly positioning ceramic balls as the solution of choice.
Toshiba Group has long recognized the potential of fine ceramic products, and won basic patents for silicon nitride compounds as early as 1974. Today, Toshiba Materials, spun off from Toshiba in October 2003, continues to advance R&D and manufacturing of silicon nitride balls, recognized for their reliability and for delivering the highest mechanical performance of any silicon balls. Its experience and record of success in bearing balls that meet demands for high speed rotation and anti-electrolytic corrosion, including machine tools, wind power generators and rolling stock, have won the company about 50% of the world market[3] . With significant increases in demand for bearings for electric vehicles on the horizon, Toshiba Materials has now decided to make this significant investment in increasing capacity.
The new production facility will be built on the company’s headquarters site, where an old building, no longer in use, will be demolished to make way for it. The new facility should be seen as the first phase of expansion, and Toshiba Materials is already considering further expansions to meet future demand growth.
Toshiba Materials will continue stable supply of high quality products, and will contribute to increased use of environmentally friendly electric vehicles.
Features of silicon nitride balls
- Low density: less than half the weight of a steel ball of the same size
- High heat resistance
- Resistant to electrolytic corrosion, as it is an insulator
- Resistant to corrosion and rust caused by acids and alkalis
- A non-magnetic material, not easily affected by a strong magnetic field
1 Electrolytic corrosion: damage to a bearing caused by a current flowing through it.
2 Bearing: A part that allows a shaft to rotate smoothly in a machine. Formed with an inner race, balls, and outer race.
3 Toshiba Materials’ investigation, July 2022
Toshiba Materials Co., Ltd. (http://www.toshiba-tmat.co.jp/en/ ) was spun off from Toshiba Corporation in 2003. With material designing technology as its core capacity, Toshiba Materials supplies materials and components essential for society’s development. Main products include metallic materials, components, fine ceramics parts and chemical materials. In the year ended March 31, 2021, net sales totaled 24.3 billion yen (approx. USD 210 million).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719006169/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
